Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Anne Umpleby"'
Autor:
Jimmy D. Bell, J. Gibney, Nicola Jackson, Anne Umpleby, S. B. Bowes, Richard H. Jones, M Stolinski, Kevin C.R. Baynes, Fariba Shojaee-Moradie, E. L. Thomas, Martin Whyte, D. Lovell, Claire Pentecost
Publikováno v:
Diabetologia. 50:404-413
AIMS/HYPOTHESIS: It is not known whether the beneficial effects of exercise training on insulin sensitivity are due to changes in hepatic and peripheral insulin sensitivity or whether the changes in insulin sensitivity can be explained by adaptive ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1fd8bc0ceb2a77c3ccadbef11b67a83
https://doi.org/10.1007/s00125-006-0498-7
https://doi.org/10.1007/s00125-006-0498-7
Autor:
Kevin C.J. Yuen, Rachel M. Williams, Tero Saukkonen, Rakesh Amin, David B. Dunger, Carlo L. Acerini, Anne Umpleby, A. P. Watts, Fariba Shojaee-Moradie
Publikováno v:
Diabetes. 55:2365-2370
Recombinant human IGF-I (rhIGF-I) complexed with its natural binding protein IGF-binding protein (IGFBP)-3 (rhIGF-I/IGFBP-3) is a novel formulation that has been shown to improve insulin sensitivity in type 1 diabetes, yet the mechanisms are not clea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc5d627d6a41f7b6bf553b584359f788
https://doi.org/10.2337/db05-1646
https://doi.org/10.2337/db05-1646
Publikováno v:
Diabetes, Obesity and Metabolism. 8:412-418
Aim: In human obesity, there is some evidence for impaired adrenergic sensitivity with respect to catecholamine-induced lipolysis. The β-adrenoceptor agonist isoprenaline has been shown to suppress plasma leptin levels in lean humans in vivo. We hyp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69684944593dc0b72fa41bf8db13c1fc
https://doi.org/10.1111/j.1463-1326.2005.00517.x
https://doi.org/10.1111/j.1463-1326.2005.00517.x
Autor:
Maryam Shahmanesh, Nicola Jackson, Fariba Shojaee-Moradie, S. Das, M Stolinski, Peter Nightingale, Anne Umpleby, W Jefferson, NJ Crabtree
Publikováno v:
Scopus-Elsevier
Background Dyslipidaemia and lipodystrophy have been described in treated HIV patients and in a small percentage of untreated HIV patients. Lipodystrophy in these patients has been shown to be associated with a lower expression of low density lipopro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdbf1b1b7fd73761fb489a0ec36d7e64
https://doi.org/10.1177/135965350501000508
https://doi.org/10.1177/135965350501000508
Autor:
J M Rosenthal, Ian A. Macdonald, Stephanie A. Amiel, Emma Bingham, Anne Umpleby, A Pernet, H. Reid, D. Smith
Publikováno v:
Diabetologia. 45:1416-1424
Aims/hypothesis. The role of glucose sensing cells in the human hepatic portal system in the initiation of the neuroendocrine responses to acute hypoglycaemia is not known. We investigated the effect of raising blood glucose concentrations in the hep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3bd57fe0b67173472402615301ee624
https://doi.org/10.1007/s00125-002-0909-3
https://doi.org/10.1007/s00125-002-0909-3
Autor:
E Albany, Paul V. Carroll, Peter J. Lumb, Peter H. Sönksen, Emanuel Christ, Anne Umpleby, David Russell-Jones, Helen Simpson, Anthony S. Wierzbicki
Publikováno v:
Clinical Endocrinology. 55:777-787
OBJECTIVES Patients with type 1 diabetes are at increased risk of cardiovascular disease, which may be related to abnormal lipid metabolism. Secretion and clearance of VLDL apolipoprotein B100 (apoB) are important determinants of plasma lipid concent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ea4b83a9f7176ebec144d34ef479beeb
https://doi.org/10.1046/j.1365-2265.2001.01407.x
https://doi.org/10.1046/j.1365-2265.2001.01407.x
Autor:
Emanuel Christ, David Russell-Jones, S B Bowes, Ian J. Gowrie, Anne Umpleby, P Croos, Roman Hovorka, Peter H. Sönksen, P V Carroll, Nicola Jackson
Publikováno v:
Diabetes. 49:789-796
Type 1 diabetes is associated with abnormalities of the growth hormone (GH)-IGF-I axis. Such abnormalities include decreased circulating levels of IGF-I. We studied the effects of IGF-I therapy (40 microg x kg(-1) x day(-1)) on protein and glucose me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30c7b54c52d66e112cb2e9c57d798e25
https://doi.org/10.2337/diabetes.49.5.789
https://doi.org/10.2337/diabetes.49.5.789
Publikováno v:
Journal of Theoretical Biology. 198:165-172
We explore the use of [15N,13C]leucine tracer to estimate whole-body fractional rates of a fast-turning-over protein pool employing synthetic data. The kinetics of [15N,13C]leucine tracer are simplified compared with those of traditional leucine trac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6443a1aad7a3251d1464eb5d15900951
https://doi.org/10.1006/jtbi.1999.0907
https://doi.org/10.1006/jtbi.1999.0907
Autor:
Anne Umpleby, Ian J. Gowrie, David Russell-Jones, Paul V. Carroll, Nicola Jackson, Roman Hovorka
Publikováno v:
American Journal of Physiology-Endocrinology and Metabolism. 276:E573-E579
Based on a mass-balance model, a surrogate measure of the whole body leucine transport into and out of cells under steady-state conditions was calculated as u/ΔTTR, where u is the infusion rate of (stable label) leucine tracer and ΔTTR is the diffe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38e6a4e0ab8f162d98b39733fcdf25db
https://doi.org/10.1152/ajpendo.1999.276.3.e573
https://doi.org/10.1152/ajpendo.1999.276.3.e573
Publikováno v:
Growth Hormone & IGF Research. 8:83-95
Although diabetes is a heterogeneous condition, IGF-I has been shown to improve glycaemic control and reduce insulin requirements in both IDDM and NIDDM. In IDDM, the therapeutic rationale for IGF-I is as a replacement therapy "topping up" low circul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcd7f0df29b5ec30a69258f98d1bc4ce
https://doi.org/10.1016/s1096-6374(98)80098-1
https://doi.org/10.1016/s1096-6374(98)80098-1